CN104478811B - Fimasartan intermediate preparation method - Google Patents
Fimasartan intermediate preparation method Download PDFInfo
- Publication number
- CN104478811B CN104478811B CN201410648222.4A CN201410648222A CN104478811B CN 104478811 B CN104478811 B CN 104478811B CN 201410648222 A CN201410648222 A CN 201410648222A CN 104478811 B CN104478811 B CN 104478811B
- Authority
- CN
- China
- Prior art keywords
- fimasartan
- methyl
- base
- preparation
- butyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- HIHUTROSIBCTJL-UHFFFAOYSA-N CCCN(C=[N]=C)C(N1N=NCCC1)=O Chemical compound CCCN(C=[N]=C)C(N1N=NCCC1)=O HIHUTROSIBCTJL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention discloses a fimasartan intermediate preparation method which is as follows: a) reacting 2-(2-n-butyl-4-hydroxy-6-methyl-pyrimidine-5-yl) acetic acid with carbonyldiimidazole in the presence of an alkali; b) reacting a product obtained by the step a) with dimethylamine to obtain 2-(2-n-butyl-4-hydroxy-6-methyl-pyrimidine-5-yl)-N, N-dimethylacetamide. Compared with the prior art, the fimasartan intermediate preparation method has the following advantages: (1) production of by-product urea is inhibited, the by-product urea is produced during the conventional preparation method, and is not easy to remove in purification process, (2) the post-processing operation procedure is simplified, the production efficiency is improved, after the end of the reaction, the product is crystallized, the target compound can be obtained by direct filtration, and (3) a large amount of extraction solvent is saved, energy consumption is saved, and the production cost is reduced. Compared with the conventional preparation method, the fimasartan intermediate preparation method is easier in industrialized application.
Description
Technical field
The invention belongs to technical field of medicine synthesis, it is specifically related to one kind and prepares Fimasartan intermediate 2- (the positive fourth of 2-
Base -4- hydroxyl -6- methyl-pvrimidine -5- base)-n, the method for n- dimethylacetylamide.
Background technology
Fimasartan is a kind of novel selective at1 ARBs, shows quick in multiple Type of Hypertensions
With effective anti-hypertension effect, very safety and have preferable tolerance, better than other same type medicines.Chemical name is 2-
Butyl -5- dimethylamino thio formyl methyl -6- methyl -3- [[2'- (1h- tetrazolium -5- base) biphenyl -4- base] methyl] is phonetic
Pyridine -4 (3h) -one, structural formula is:
Korean patent document kp256359 describes to prepare the method for Fimasartan, intermediate formula 1 in the presence of base with
4- [2- (n- triphenyl methyl tetrazole) -5- base phenyl] benzyl bromine reaction, makes the product thioamides of gained using lawesson reagent
Change, and in acid condition deprotection group to prepare Fimasartan.
As it appears from the above, intermediate formula 1 is to prepare the necessary intermediate of Fimasartan, steady quality to be obtained reliably non-horse
Husky smooth it is necessary to Fimasartan intermediate 2- (2- normal-butyl -4- hydroxyl -6- methyl-pvrimidine -5- base)-n, n- dimethyl second
The synthetic method of acid amides carries out in-depth study.
Korea S's 10-521980 patent document describes a kind of preparation method of Fimasartan intermediate, reaction scheme
As follows:
As shown in scheme, when using n- hydroxybenzotriazole (hobt), n- methyl morpholine and dicyclohexylcarbodiimide
(dcc), when being imine group by the functional end-group of formula b and converting carboxylate groups, there are the shortcoming producing accessory substance urea, urea due to
Its high-moisture absorbability characteristic and not easily pass through common centrifugal filtration.
For the defect producing accessory substance urea, patent document wo 2011/090323a2 proposes 2 kinds of new Fimasartans
The preparation method of intermediate, wherein method 1 are reacted with pentamidinum or its salt in the presence of base using the compound of formula 4, synthesis
Route is as follows:
Wherein r1Represent c1-c6Linear or branched alkyl or c3-c6Cycloalkyl.
Method 2 is reacted with the compound of formula 5 in the presence of base using the compound of formula 2, products therefrom again with dimethylamine
Reaction, synthetic route is as follows:
Wherein r represents c1-c6Alkyl, c3-c6Cycloalkyl, phenyl or benzyl, and y represents cl, br or i.
As above prepare the method for Fimasartan intermediate although the formation of accessory substance urea can be suppressed for 2 kinds, but have one altogether
Same defect, it is simply that post-reaction treatment is very complicated, is required for taking the techniques such as concentration, extraction, crystallization, and solvent usage amount is big, energy
Consumption is high, is not suitable for industrialized production.
Content of the invention
It is an object of the invention to provide one kind prepares Fimasartan intermediate 2- (2- normal-butyl -4- hydroxyl -6- methyl-phonetic
Pyridine -5- base)-n, the method for n- dimethylacetylamide, methods described be not only able to suppress accessory substance urea generation moreover it is possible to simplify after
Process operating procedure, reduces cost, be particularly suitable for industrialized production.
For realizing this purpose, the present invention provides one kind to prepare Fimasartan intermediate 2- (2- normal-butyl -4- hydroxyl -6- first
Base-pyrimidine -5- base)-n, the method for n- dimethylacetylamide, the method comprising the steps of:
A) compound 2- (2- normal-butyl -4- hydroxyl -6- methyl-pvrimidine -5- the base)-acetic acid of formula 2 and the compound of formula 3 are made
Carbonyl dimidazoles react in the presence of base, and
B) so that the product of step a) and dimethylamine is reacted, obtain the compound shown in formula 1: 2- (2- normal-butyl -4- hydroxyl -
6- methyl-pvrimidine -5- base)-n, n- dimethylacetylamide；
Its compound structure shown in Chinese style 1 is as follows:
Compound structure shown in formula 2 is as follows:
Compound structure shown in formula 3 is as follows:
In the preparation process in accordance with the present invention, the compound shown in formula 2 can be commercially available or be prepared by known methods, for example
Method described in Korea S's 10-0521980 patent document.
In the preparation process in accordance with the present invention, the compound carbonyl dimidazoles shown in formula 3 use as carboxyl activator, carboxyl
After carbonyl dimidazoles activation, easily with dimethylamine, condensation reaction can occur, this compound can be commercially available.
In the preparation process in accordance with the present invention, the mol ratio of the compound shown in step a) Chinese style 2 and the compound shown in formula 3
In the scope of 1:1～2, preferably 1:1.1.Reduce shown in formula 3 on the basis of the reaction completely of compound shown in guarantee formula 2
The usage amount of compound, reduces preparation cost, reduces post-processing difficulty simultaneously.
In the preparation process in accordance with the present invention, the model in 1:1～3 for the mol ratio of the compound shown in step a) Chinese style 2 and alkali
In enclosing, preferably 1:2.The mole that alkali adds is excessively it is ensured that the reaction of step a) is complete.
In the preparation process in accordance with the present invention, the wherein compound shown in step a) Chinese style 2 and the rubbing of dimethylamine in step b)
Your ratio in the scope of 1:1～3, preferably 1:2.The mole of dimethylamine is excessive, ensure that middle product prepared by step a)
The abundant reaction of thing.
In the preparation process in accordance with the present invention, the alkali in step a) is n- methyl morpholine, triethylamine, trimethylamine, tri-isopropyl amine
Or at least one in diisopropylethylamine, preferably n- methyl morpholine.
In the preparation process in accordance with the present invention, in step a), after the compound shown in formula 2 is added solvent, add alkali, so
Add the compound shown in formula 3, following reaction afterwards.Add and can have interval between the compound shown in alkali and addition formula 3.But
It is that the present invention is not limited to such order of addition.
In the preparation process in accordance with the present invention, the reaction temperature of step a) is preferably in 0～35 DEG C of scope, during reaction
Reaction temperature can change, and the reaction time is preferably in the scope of 10 minutes～2 hours, and can be become according to reaction temperature etc.
Change.
In the preparation process in accordance with the present invention, use identical solvent dmf or dmac (dimethyl in step a) neutralization procedure b)
Acetamide), preferably dmf.The amount of reaction dissolvent is within the scope of used by common reactant, and formula 2 institute of preferably every weight
The compound showing is using the reaction dissolvent of about 5～10 times of volumes (g/ml), more preferably from about 5 times volumes.
In the preparation process in accordance with the present invention, in step b), the product of step a) is with unsegregated state (original position shape
State) compound that uses.
In the preparation process in accordance with the present invention, the dimethylamine in step b) is alcoholic solution or the tetrahydrofuran solution of dimethylamine,
This solution can commercially available it is also possible to be prepared with triethylamine react by dimethylamine hydrochloride.Preferably, described diformazan
The concentration of the alcoholic solution of amine or tetrahydrofuran solution is preferably 1-3mol/l, more preferably 2mol/l.
In the preparation process in accordance with the present invention, the reaction temperature of step b) is preferably in 0～35 DEG C of scope, during reaction
Reaction temperature can change, and the reaction time, and can be according to reaction temperature, anti-preferably in the scope of 30 minutes～10 hours
Solvent etc. is answered to change.
In the preparation process in accordance with the present invention, after the reaction in step b) terminates, target product is in the form of crystallizing from reaction
Separate out in liquid, filter, ethyl acetate washing can get highly purified Fimasartan intermediate.For ensureing the pure of final products
Degree, reduces post-processing difficulty, after the reaction in step b) terminates, preferably, last handling process is simultaneously:
After reaction terminates, the solid that addition ethyl acetate is dispersed to precipitate, it is cooled to 0～5 DEG C of growing the grain 1～2 hour, filter,
Ethyl acetate drip washing, is dried to obtain 2- (2- normal-butyl -4- hydroxyl -6- methyl-pvrimidine -5- base)-n, n- dimethylacetylamide
White powder, purity is more than 95%.
In above-mentioned last handling process, dissipate reaction in the volume generally step a) that the solid with ethyl acetate separating out adds molten
2-4 times of agent volume, more preferably 3 times.
Compared with prior art, the preparation method of the Fimasartan intermediate of the present invention has the advantage that
(1) suppress the generation of accessory substance urea, described accessory substance urea produces and in purge process in customary preparation methods
In be difficult remove.
(2) post-processing operation program, improve production efficiency are simplified, reaction terminates rear product crystallization and separates out, and direct filtration is
Obtain target compound.
(3) save the use of a large amount of extractants, saving energy consumption, reduce production cost.Compared with customary preparation methods more
It is easy to industrial applications.
Brief description
The Fimasartan intermediate 2- (2- normal-butyl -4- hydroxyl -6- methyl-pvrimidine -5- that Fig. 1 prepares for embodiment 1
Base)-n, the nuclear magnetic spectrogram of n- dimethylacetylamide.
Specific embodiment
With reference to specific embodiment, the present invention is further detailed explanation.These non-limiting examples only for
Illustrate that the present invention provides, and the method that embodiment discloses, it is not construed as limiting the scope of the present invention.
Embodiment 1
In the reaction bulb of 500 milliliters of clean dried, add dmf (55ml), the compound 2- (2- normal-butyl -4- hydroxyl of formula 2
Base -6- methyl-pvrimidine -5- base)-acetic acid (11g, 49.1mmol), n- methyl morpholine (9.9g, 98.2mol), stirring suspension.10
Add carbonyl dimidazoles (8.8g, 54.0mmol) after minute, system gradually becomes clarification, reaction 1 hour is stirred at room temperature, add concentration
Dimethylamine tetrahydrofuran solution (50ml, 100mmol) for 2mol/l, is stirred at room temperature half an hour, and a large amount of solids separate out.Add
165ml ethyl acetate disperses, and is cooled to 0～5 DEG C of growing the grain 1 hour, filters, a small amount of ethyl acetate drip washing, is vacuum dried white
Powder title compound (2- (2- normal-butyl -4- hydroxyl -6- methyl-pvrimidine -5- base)-n, n- dimethylacetylamide) 10.5g
(41.7mmol, yield 85.2%).The product structure detection data that this embodiment prepares is as follows:
H-nmr (400mhz, cdcl3):0.85(t,3h),1.30(m,2h),1.65(m,2h),2.25(s,3h),2.53
(t, 2h), 2.89 (s, 3h), 3.09 (s, 3h), 3.49 (s, 2h), nuclear magnetic spectrogram is as shown in Figure 1.
Embodiment 2
In the reaction bulb of 500 milliliters of clean dried, add dmac (50ml), the compound 2- (2- normal-butyl -4- hydroxyl of formula 2
Base -6- methyl-pvrimidine -5- base)-acetic acid (10g, 44.6mmol), n- methyl morpholine (9.0g, 89.2mmol), stirring suspension.10
Add carbonyl dimidazoles (8.0g, 49.1mmol) after minute, system gradually becomes clarification, reaction 1 hour is stirred at room temperature, add concentration
Dimethylamine tetrahydrofuran solution (44.6ml, 89.2mmol) for 2mol/l, is stirred at room temperature half an hour, and a large amount of solids separate out.Plus
Enter the dispersion of 150ml ethyl acetate, be cooled to 0～5 DEG C of growing the grain 1 hour, filter, a small amount of ethyl acetate drip washing, be vacuum dried in vain
Color powder title compound 9.8g (38.9mmol, yield 87.2%).Structure detection data consistent with Example 1.
Embodiment 3
(1) prepare dimethylamine tetrahydrofuran solution
In 100 milliliters of clean dried reaction bulbs, add 50 milliliters of dry tetrahydrofuran, stirring is lower to add dimethylamine hydrochloride
(8.2g, 100.6mmol), triethylamine (11.2g, 110.7mmol), be stirred at room temperature 30 minutes standby.
(2) Fimasartan intermediate 2- (2- normal-butyl -4- hydroxyl -6- methyl-pvrimidine -5- base)-n, n- dimethylacetamide
The preparation of amine
In the reaction bulb of 500 milliliters of clean dried, add dmf (57ml), the compound 2- (2- normal-butyl -4- hydroxyl of formula 2
Base -6- methyl-pvrimidine -5- base)-acetic acid (11.3g, 50.3mmol), n- methyl morpholine (10.1g, 100.6mol), stirring is outstanding
Floating.Add carbonyl dimidazoles (9.0g, 55.3mmol) after 10 minutes, system gradually becomes clarification, reaction 1 hour is stirred at room temperature, plus
Enter the dimethylamine tetrahydrofuran solution that step (1) prepares, be stirred at room temperature, a large amount of solids separate out half an hour.Add 170ml acetic acid
Ethyl ester disperses, and is cooled to 0～5 DEG C of growing the grain 1 hour, filters, a small amount of ethyl acetate drip washing, is vacuum dried to obtain white powder title
Compound 10.6g (42.1mmol, yield 83.7%).Structure detection data consistent with Example 1.
Claims (8)
1. a kind of preparation method of Fimasartan intermediate, comprises the following steps:
A) 2- (2- normal-butyl -4- hydroxyl -6- methyl-pvrimidine -5- base)-acetic acid is reacted in the presence of base with carbonyl dimidazoles；
Described 2- (2- normal-butyl -4- hydroxyl -6- methyl-pvrimidine -5- base)-acetic acid is 1:1～3 with the mol ratio of alkali；
B) step a) reaction is not completely, post-treated, directly reacts with dimethylamine, obtains Fimasartan intermediate: 2- (the positive fourth of 2-
Base -4- hydroxyl -6- methyl-pvrimidine -5- base)-n, n- dimethylacetylamide；
Described 2- (2- normal-butyl -4- hydroxyl -6- methyl-pvrimidine -5- base)-n, the structure of n- dimethylacetylamide is as follows:
The structure of described 2- (2- normal-butyl -4- hydroxyl -6- methyl-pvrimidine -5- base)-acetic acid is as follows:
The structure of described carbonyl dimidazoles is as follows:
2. the preparation method of Fimasartan intermediate according to claim 1 is it is characterised in that described alkali is n- methyl
At least one in quinoline, triethylamine, trimethylamine, tri-isopropyl amine or diisopropylethylamine.
3. the preparation method of Fimasartan intermediate according to claim 1 it is characterised in that described 2- (2- normal-butyl-
4- hydroxyl -6- methyl-pvrimidine -5- base) mol ratio of-acetic acid and carbonyl dimidazoles is 1:1～2.
4. the preparation method of Fimasartan intermediate according to claim 1 it is characterised in that described 2- (2- normal-butyl-
4- hydroxyl -6- methyl-pvrimidine -5- base) mol ratio of-acetic acid and dimethylamine is 1:1～3.
5. the preparation method of Fimasartan intermediate according to claim 1 is it is characterised in that the reaction that adopts of step a)
Solvent is dmf or dmac.
6. the Fimasartan intermediate according to Claims 1 to 4 any claim preparation method it is characterised in that
In step b), described dimethylamine is alcoholic solution or the tetrahydrofuran solution of dimethylamine.
7. the preparation method of Fimasartan intermediate according to claim 6 is it is characterised in that the alcohol of described dimethylamine is molten
The concentration of liquid or tetrahydrofuran solution is 1-3mol/l.
8. the Fimasartan intermediate according to Claims 1 to 4 any claim preparation method it is characterised in that
After step b) reaction terminates, obtain Fimasartan intermediate through post processing, described last handling process is: after reaction terminates, plus
Enter the solid that ethyl acetate is dispersed to precipitate, be cooled to 0～5 DEG C of growing the grain 1～2 hour, filter, ethyl acetate drip washing, be dried to obtain
2- (2- normal-butyl -4- hydroxyl -6- methyl-pvrimidine -5- base)-n, the white powder of n- dimethylacetylamide.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410648222.4A CN104478811B (en) | 2014-11-14 | 2014-11-14 | Fimasartan intermediate preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410648222.4A CN104478811B (en) | 2014-11-14 | 2014-11-14 | Fimasartan intermediate preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104478811A CN104478811A (en) | 2015-04-01 |
| CN104478811B true CN104478811B (en) | 2017-01-25 |
Family
ID=52753444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410648222.4A Active CN104478811B (en) | 2014-11-14 | 2014-11-14 | Fimasartan intermediate preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104478811B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113336709B (en) * | 2021-06-25 | 2022-06-03 | 上海立科化学科技有限公司 | Preparation method of N, N-dimethylacetamide |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100521980B1 (en) * | 2002-10-10 | 2005-10-17 | 보령제약 주식회사 | The preparation method for pyrimidinone compound and trihydrate of the salt of the pyrimidinone compound |
| CN102666496B (en) * | 2010-01-21 | 2015-05-20 | 保宁制药株式会社 | New preparation of 2-(2-n-butyl-4-hydroxy-6-methyl-pyrimidine-5-yl)-n,n-dimethylacetamide |
-
2014
- 2014-11-14 CN CN201410648222.4A patent/CN104478811B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104478811A (en) | 2015-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101239985B (en) | Method for preparing cefodizime sodium | |
| CN102286003B (en) | Manufacture method of ceftazidime compound | |
| CN104130273B (en) | A kind of synthetic method of ceftriaxone sodium | |
| CN104974060A (en) | Method for preparing sodium, 8-(2-hydroxybenzamido)octanoate | |
| CN101817795A (en) | Improved method for synthesizing valsartan | |
| CN101921284A (en) | Preparation method of cefathiamidine | |
| US10538507B2 (en) | Preparation process for high-purity dabigatran etexilate | |
| CN102351735A (en) | Preparation method of Iopromide | |
| CN104478811B (en) | Fimasartan intermediate preparation method | |
| CN103724288B (en) | Triethyl orthoformate legal system is for the post-treating method of 1H-tetrazole-1-acetic acid | |
| CN104277053B (en) | A kind of preparation method of Cefodizime and its intermediate cefodizime acid | |
| CN103319503A (en) | Preparation method of cefdinir | |
| CN105399667A (en) | Preparation method of edoxaban intermediate | |
| CN104341435B (en) | The process for purification of ceftriaxone sodium | |
| CN103113294B (en) | The synthetic method of rebamipide | |
| CN104193766A (en) | Method for preparing cefetamet acid | |
| CN110330447B (en) | Preparation method and application of nafamostat mesylate intermediate | |
| CN108299470B (en) | Preparation method of cefteram pivoxil | |
| CN103755577B (en) | A kind of method reclaiming Transbroncho alkali from Ambroxol HCl refinement mother liquor | |
| CN101293891B (en) | Method for preparing ceftazidime midbody | |
| CN101712687B (en) | Method for preparing intermediate of cefetamet pivoxil hydrochloride | |
| CN102584804B (en) | A kind of technique of preparing olmesartan medoxomil with trityl olmesartan medoxomil deprotection base | |
| CN102898443B (en) | The process for purification of high yield super-clean high-purity Cefodizime Sodium | |
| CN102850380B (en) | Preparation method of cefodizime acid | |
| JP2013531020A (en) | Method for preparing crystalline form A of 2- [3-cyano-4- (2-i-butoxy) phenyl] -4-methyl-5-thiazole-carboxylic acid (febuxostat) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |